Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
Vincent Chau, Marijo Bilusic Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USACorrespondence: Marijo Bilusic Tel +1-301-765-4457Fax +1-240-541-4548Email marijo.bilusic@nih.govAbstract: Over the last 18 mon...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2020-08-01
|
| Serija: | Cancer Management and Research |
| Teme: | |
| Online pristup: | https://www.dovepress.com/pembrolizumab-in-combination-with-axitinib-as-first-line-treatment-for-peer-reviewed-article-CMAR |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|